Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BilGemCap: Adjuvant Gemcitabine + Capecitabine vs Capecitabine in Biliary Tract Cancer
NCT04401709Phase 3Unknown
- Sponsor
- Samsung Medical Center
- Start
- Apr 2021
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of gemcitabine in biliary tract cancer (BTC), sponsored by Samsung Medical Center. Status: unknown.
02
Drugs
gemcitabine
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT04401709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04401709.